SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?


To: Ariella who wrote (225)11/18/1998 8:45:00 PM
From: Rick Strange  Read Replies (1) | Respond to of 1386
 
Another story about BOL: "Bausch & Lomb May Dump Eyeware BIZ"

biz.yahoo.com

CEO says greatest potential in health-care business. If he is serious, let's see what BOL can do next quarter with Lotemax and Alrex.



To: Ariella who wrote (225)11/19/1998 10:04:00 AM
From: ADEL 7  Respond to of 1386
 
I sounded very negative yesterday but I have not and will not sell any share for 110-15 years. All I hope for is to get that deal for TBI soon. No reason to waste time.
We have a great drug that can help thousands and thousands of patients and getting it on the market soon will be the ethical thing PARS management can do. Just yesterday I had one patient with high ICP, all I can do is to give him mannitol and steroid( I wished I had HU-211). All I ask the management is to look at this matter as something has to be done urgently so that many lives can be saved.
Any how I am going on vacation for 6 weeks.
Happy new year to PARS investors.
Adel



To: Ariella who wrote (225)11/21/1998 6:17:00 AM
From: Gabe Fernandez  Read Replies (1) | Respond to of 1386
 
Ariella in regards to having to educate neurologists you have to make the distinction between neurologists and neurosurgeons. I can see the neurologist main interest would be strokes versus the neurosurgeons greater interest in head trauma.